Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Roche Cobas C. Diff Test

NEW YORK (GenomeWeb) – The US Food and Drug Administration has granted 510(k) clearance to a Clostridium difficile test from Roche, the firm announced today.

The test detects the C. diff toxin B gene from stool samples. It runs on Roche's cobas 4800 system, which combines automated sample preparation with real-time PCR amplification and detection for mixed batch testing.

"The cobas Cdiff Test requires less sample handling and provides laboratories with a simplified workflow when compared to other molecular methods," Paul Brown, head of Roche Molecular Diagnostics, said in a statement. "It also delivers a lower inhibition rate, which means fewer repeat samples and chances for error, enabling better patient care."

The test adds to the US infectious disease menu on the cobas 4800, which also includes assays for Chlamydia trachomatis/Neisseria gonorrhoeae and human papilloma virus. A test for Staphylococcus aureus and methicillin-sensitive S. aureus was FDA cleared this year.

The cobas 4800 platform also runs an assay for the BRAF V600 mutation, which is cleared as a companion diagnostic for the melanoma drugZelboraf (vemurafenib), and an EGFR test that is acompanion diagnostic for Tarceva (erlotinib). A KRAS mutation assay on the 4800 was cleared earlier this month.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.